The risk of cardiovascular diseases induced by radiotherapy

Česká verzia

Authors: K. Hudecová; D. Urbanová; H. Petrášová
Authors place of work: Ústav patologickej fyziológie, Oddelenie klinickej patofyziológie Lekárskej fakulty UK Bratislava, Slovenská republika, prednosta doc. MUDr. Marián Bernadič, CSc., mim. prof.
Published in the journal: Vnitř Lék 2008; 54(6): 646-652
Category: Reviews

Summary

At present the number of cancer survivors is still increasing. However, their long-term quality of life after anticancer treatment can be decreased. Radiotherapy may represent a risk for the future of some oncologic patients. The late cardiovascular effects of radiotherapy to the area of thorax, cranium and to the abdominal area are the actual multidisciplinary problem. The unique problem is mediastinal radiotherapy which may induce the development of the cardiomyopathy, constrictive pericarditis, coronary artery disease, myocardial infarction, valvular defects, arrhythmias and other complications. Exact knowledge of pathophysiological mechanisms of radiation induced cardiovascular damage after radiotherapy as well as using of new diagnostic cardiologic methods might be useful for the detection of subclinical abnormalities and their early treatment already in the asymptomatic patients.

Key words:
radiotherapy - cardiovascular diseases - breast cancer - Hodgkin´s disease - metabolic syndrome

Zdroje

1. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002; 29: 2391-2401.

2. Adams MJ, Lipshultz SE. Pathophysiology of antracycline - and radiation-associated cardiomyophaties: implications for screening and prevention. Pediatr Blood Cancer 2005; 44: 600-606.

3. Adams MJ, Hardenbergh PH, Constine LS et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45: 55-75.

4. Couto-Silva AC, Brauner R, Adan LF. Endocrine sequelae after radiotherapy in childhood and adolescence. Arq Bras Endocrinol Metabol 2005; 49: 825-832.

5. Birkholz D, Korpal-Szczyrska M, Kaminska H et al. Influence of surgery and radiotherapy on growth and pubertal development in children treated for brain tumour. Med Wieku Rozwoj 2005; 9: 463-469.

6. Oeffinger KC, Mertens AC, Sklar CA et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21: 1359-1365.

7. Ross JA, Oeffinger KC, Davies SM et al. Genetic variation in the leptin receptor and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004; 22: 3558-3562.

8. Link K, Moël Ch, Garwicz S et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrin Met 2004; 89: 5003-5012.

9. Follin C, Thilén U, Ahrén B et al. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrin Met 2006; 91: 1872-1875.

10. Gurney JG, Ness KK, Sibley SD et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006; 107: 1303-1312.

11. Tahrani AA, Cramp C, Moulik P. The development of non-insulin-dependent diabetes after total body irradiation and bone marrow transplantation in adolescence: a case report and literature review. Pediatr Diabetes 2006; 7: 173-175.

12. Kourti M, Tragiannidis A, Makedou A et al. Metabolic syndrome in children and adolescent with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol 2005; 27: 499-501.

13. Mladosievičová B, Kaiserová E, Foltinová A (eds). Možné neskoré následky protinádorovej liečby v detstve. Bratislava: SAP 2007.

14. Adams MJ, Lipshultz SE, Schwartz C et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 2003; 13: 346-356.

15. Adams MJ, Hardenbergh PH, Constine LS et al. Radiation-associated cardiovascular disease. Crit Rev Hematol 2003; 45: 55-75.

16. Dabaja B, Cox JD, Buchholz TA. Radiation therapy can still be used safely in combined modality approaches in patients with Hodgkin´s lymphoma. J Clin Oncol 2007; 25: 3-5.

17. Girinsky T, van der Maazen R, Specht L et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270-277.

18. Koontz BF, Kirkpatrick JP, Clough RW et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: Cure balanced against complications. J Clin Oncol 2006; 24: 605-611.

19. Diehl V, Brillant C, Engert A et al. Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG). J Clin Oncol 2005; 23: 56.

20. Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol) 2005; 17: 153-159.

21. Moser CM, Noordijk EM, van Leeuwen FE et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107: 2912-2919.

22. Miltenyi Z, Gergely L, Illes A Chronic pericarditis in Hodgkin disease. Orv Hetil 2002; 143: 2687-2689.

23. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005; 32(2, Suppl 3): 71-80.

24. Guldner L, Haddy N, Pein F et al. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer. Radiother Oncol 2006; 81: 47-56.

25. Elbl L, Vásová I, Navrátil M et al. Pozdní kardiotoxicita u nemocných léčených pro maligní lymfomy chemoterapií s doxorubicinem. Vnitř Lék 2006; 52: 328-338.

26. Aleman BMP, van den Belt-Duseboud AW, De Bruin ML et al. Late cardiac toxicity after treatment for Hodgkin´s lymphoma. Blood 2007; 109: 1878-1886.

27. Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin´s disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148.

28. Gayed IW, Liu HH, Yusulf SW et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 2006; 47: 1756-1762.

29. Hull MC, Morris CG, Pepine CJ et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831-2837.

30. Charniot JC, Zerhouni K, Kidouche R et al. Late cardiac complications of radiation therapy. Presse Med 2006; 35: 239-242.

31. Vazhenin AV, Fokin AA, Tereshin OS Arteropathy as late-onset complication of radiotherapy for malignant tumor. Vopr Onkol 2005; 51: 485-488.

32. Patel DA, Kochanski J, Suen AW et al. Clinical manifestation of noncoronary atherosclerotic vascular disease after moderate dose of irradiation. Cancer 2006; 106: 718-725.

33. Gaugler MH, Vereycken-Holler V, Squiban C et al. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 2005; 163: 479-487.

34. Bonneterre J, Roche H, Kerbrat P et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol 2004; 22: 3070-3079.

35. Evans ES, Prosnitz RG, Yu X et al. Impact of patient - specific risk factors, irradiated left ventricular volume, and treatment set-up errors on the development of myocardial perfusion defects after radiation therapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2006; 66: 1125-1134.

36. Hooning MJ, Botma A, Aleman BMP et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. Eur J Cancer 2007; 99: 365-375.

37. Harris EE, Correa C, Hwang WT et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006; 24: 4100-4106.

38. Mladosievičová B, Foltinová A, Bernadič M et al. Signal-averaged ECG in patients after anthracycline therapy for childhood cancer. Neoplasma 1998; 45: 40-45.

39. Trněný M, Bělohlávek O, Kořen J et al. Výsledek celotělového FDG-PET vyšetření predikuje osud nemocných s difuzním velkobuněčným lymfomem jak při použití v intermediárním stagingu, tak při použití na konci standardní chemoterapie. Vnitř Lék 2007; 53: 936-941.

40. Galderisi M, Marra F, Esposito R et al. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007; 5: 4.

41. Bilora F, Pietrogrande F, Petrobelli F et al. Is radiation a risk factor for atherosclerosis? An echo-color Doppler study on Hodgkin and non-Hodgkin patients. Tumori 2006; 92: 295-298.

42. Heidenreich PA, Schnittger I, Strauss HW et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin´s disease. J Clin Oncol 2007; 25: 43-49.

43. Apter S, Shemesh J, Raanani P et al. Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation. Coron Artery Dis 2006; 17: 145-151.

44. Jingu K, Nemoto K, Kaneta T et al. Temporal change in brain natriuretic peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1417-1423.

45. Wondergem J, Strootman EG, Frlich M et al. Circulating atrial natriuretic peptide plasma levels as a marker for cardiac damage after radiotherapy. Radiother Oncol 2001; 58: 295-301.

46. Wondergem J, Persons K, Zurcher CH et al. Changes in circulating atrial natriuretic peptide in relation to the cardiac status of Rhesus monkeys after total-body irradiation. Radiother Oncol 1999; 53: 67-75.

47. Urbanová D, Mladosievičová B. Kardiotoxicita antracyklínovej liečby vo svetle nových biochemických diagnostických možností. Vnitř Lék 2007; 53: 669-677.

48. Horáček JM, Pudil R, Tichý M et al. Biochemical markers assessment of cardiotoxicity during preparative regimen and haematopoietic cell transplantation in acute leukemia. Exp Oncol 2007; 29: 243-247.

49. Auner HW, Tinchon C, Brezinschek RI et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002; 69: 1-6.

50. Radvanský J, Radvanská J, Slabý K et al. Late treatment sequelae of Hodgkin disease in a cohort of long-term survivors treated at the department of pediatric oncology, Motol. Klin Onkol 2004; 17: 131-135.